Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004049281 | SCV002615971 | uncertain significance | not specified | 2022-09-16 | criteria provided, single submitter | clinical testing | The p.V1211I variant (also known as c.3631G>A), located in coding exon 4 of the ALPK2 gene, results from a G to A substitution at nucleotide position 3631. The valine at codon 1211 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003961000 | SCV004768999 | benign | ALPK2-related disorder | 2019-12-05 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |